A microRNA-based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study

Miyoshi, Jinsei; Zhu, Zhenzhen; Luo, Aiping; Toden, Shusuke; Xu, Zhou; Izumi, Daisuke; Kanda, Mitsuro; Takayama, Tetsuji; Parker, Iqbal; Wang, Minjie; Gao, Feng; Zaidi, Ali H.; Baba, Hideo; Kodera, Yasuhiro; Cui, Yongping; Wang, Xin; Liu, Zhihua; Goel, Ajay

doi:10.1186/s12943-022-01507-x

Cited by 41 publications

(25 citation statements)

References 42 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…m5C, as a common RNA modification type, has displayed significant value in the diagnosis of several cancers (9,29). miRNAs have been identified as excellent candidate noninvasive biomarkers because of their high stability and abundance in serum (30,31). Therefore, numerous studies have evaluated the diagnostic potential of various miRNAs, such as miR-320b, miR-125b, miR-221-3p, and miR-124-3p (32)(33)(34)(35).…”

Section: Discussionmentioning

confidence: 99%

Construction of a serum diagnostic signature based on m5C-related miRNAs for cancer detection

et al. 2023

View full text Add to dashboard Cite

Currently, no clinically relevant non-invasive biomarkers are available for screening of multiple cancer types. In this study, we developed a serum diagnostic signature based on 5-methylcytosine (m5C)-related miRNAs (m5C-miRNAs) for multiple-cancer detection. Serum miRNA expression data and the corresponding clinical information of patients were collected from the Gene Expression Omnibus database. Serum samples were then randomly assigned to the training or validation cohort at a 1:1 ratio. Using the identified m5C-miRNAs, an m5C-miRNA signature for cancer detection was established using a support vector machine algorithm. The constructed m5C-miRNA signature displayed excellent accuracy, and its areas under the curve were 0.977, 0.934, and 0.965 in the training cohort, validation cohort, and combined training and validation cohort, respectively. Moreover, the diagnostic capability of the m5C-miRNA signature was unaffected by patient age or sex or the presence of noncancerous disease. The m5C-miRNA signature also displayed satisfactory performance for distinguishing tumor types. Importantly, in the detection of early-stage cancers, the diagnostic performance of the m5C-miRNA signature was obviously superior to that of conventional tumor biomarkers. In summary, this work revealed the value of serum m5C-miRNAs in cancer detection and provided a new strategy for developing non-invasive and cost effective tools for large-scale cancer screening.

show abstract

Section: Discussionmentioning

confidence: 99%

Construction of a serum diagnostic signature based on m5C-related miRNAs for cancer detection

et al. 2023

View full text Add to dashboard Cite

show abstract

“…First, serum miR-21 expression levels are stable and reproducible. One explanation for this remarkable stability is that miRNAs might be chemically modified ( e.g ., methylation), making them resistant to ribonu-clease activity ( Miyoshi et al, 2022 ). Second, when compared with histopathological examination, serum or plasma miR-21 is characterized by minimal invasion and convenience and easily detected by qRT-PCR.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-21 as a potential biomarker for detecting esophageal carcinoma in Asian populations: a meta-analysis

Han¹,

Pan²,

Lu³

et al. 2022

PeerJ

View full text Add to dashboard Cite

Background MicroRNA-21 (miR-21) is significantly expressed in a variety of cancers and could be used as a tumor biomarker. However, the results are varied, and no studies on the diagnostic usefulness of miR-21 in Asian esophageal cancer (EC) patients have been published. This meta-analysis was aimed at exploring whether miR-21 can be used as a diagnostic marker and assessing its effectiveness. Methods The relevant literature was identified in six main databases: Ovid MEDLINE, PsycINFO, PubMed MEDLINE, Embase, Web of Science, and the Cochrane Library. Two researchers independently selected the literature based on the inclusion and exclusion criteria, extracted data, and evaluated the risk of bias. The meta-analysis was carried out using Review Manager 5.4, Meta-Disc 1.4 and STATA 15.1 software. In the end, 987 patients from 12 different studies were included. Quality evaluation of diagnostic accuracy studies 2 (QUADAS—2) was used to examine the risk of bias. Results The pooled sensitivity (SEN) was 0.72 (95% CI [0.69–0.75]), the pooled specificity (SPE) was 0.78 (95% CI [0.75–0.81]), the pooled positive likelihood ratio (PLR) was 2.87 (95% CI [2.28–3.59]), the pooled negative likelihood ratio (NLR) was 0.36 (95% CI [0.31–0.43]), the pooled diagnostic odds ratio (DOR) was 10.00 (95% CI [7.73–12.95]), and the area under the curve 0.82 (95% CI [0.79–0.85]). A Deeks’ funnel plot shows that there was no publication bias (P = 0.99). Conclusion Our findings suggest miR-21 might be the potential biomarker for detecting EC in Asian populations, with a good diagnostic value.

show abstract

“…These results suggest that the risk assessment tool used in non-incidence areas may not accurately distinguish risk levels, and further risk stratification methods need to be developed to identify high-risk individuals. Numerous studies have indicated that multiple biomarkers such as tumor-associated antigens, autoantibodies, miRNAs, and methylated DNA markers exhibit good performance for the early detection and diagnosis of EC and GC (21)(22)(23)(24)(25)(26). Thus, the combination of epidemiological risk factors (obtained by the questionnaire) and promising biomarkers, which may be used to develop risk prediction models, may help to optimize the risk stratification and improve screening efficacy.…”

Section: Discussionmentioning

confidence: 99%

A cluster randomized controlled trial to evaluate the efficacy of esophageal and gastric cancer screening in mortality reduction in a non-high-incidence area: methodology and initial results

Wang¹,

Liu²,

Xu³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: A cluster randomized controlled trial of endoscopy-based screening for esophageal cancer (EC) and gastric cancer (GC) was conducted to evaluate the efficacy and feasibility of this strategy in a nonhigh-incidence rural area of China. The trial design and baseline findings are presented here.Methods: A total of 33 eligible villages in Luoshan County in Henan Province were assigned randomly to the intervention or control group in a 1:1 ratio by a computer-generated randomization list. Local residents aged 40 to 69 years were enrolled from the villages. Participants in the intervention group were risk-stratified with a questionnaire, and high-risk individuals were subsequently screened by endoscopy. The primary outcomes were EC and GC mortality. The secondary outcomes comprised the detection rate, stage distribution, and the treatment rate. In this study, baseline characteristics were assessed by a questionnaire.Multivariate logistic regression analysis was performed to explore factors associated with endoscopy compliance.Results: Trial recruitment was completed in 2017, and ultimately, there were 12,475 and 11,442 participants allocated to the intervention (17 clusters) and the control group (16 clusters), respectively. We included 23,653 participants in the analysis, with 12,402 in the intervention group and 11,251 in the control group.A total of 6,286 (50.7%) participants in the intervention group were estimated as high-risk individuals, and 2,719 (43.3%) underwent endoscopy. Multivariate logistic regression analysis demonstrated that some factors including age, gender, education, personality and mental health, and upper gastrointestinal diseases or symptoms might affect endoscopy compliance. The detection rates for positive cases of EC and GC were 0.22% and 0.55%, respectively. The rates for esophageal and gastric precancerous lesions were 0.70% and 2.35%, respectively. The early detection rates for EC and GC were 50.0% and 33.3%, respectively.Additionally, the overall treatment rate for positive cases was 90.0%. Conclusions:The diagnostic yield of endoscopy-based screening for EC and GC was relatively low in a non-high-incidence rural area. The study may offer clues for the improvement of endoscopy compliance and the optimization of screening strategies for upper gastrointestinal cancer in non-high-incidence areas.

show abstract

A microRNA-based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study

Cited by 41 publications

References 42 publications

Construction of a serum diagnostic signature based on m5C-related miRNAs for cancer detection

Construction of a serum diagnostic signature based on m5C-related miRNAs for cancer detection

MicroRNA-21 as a potential biomarker for detecting esophageal carcinoma in Asian populations: a meta-analysis

A cluster randomized controlled trial to evaluate the efficacy of esophageal and gastric cancer screening in mortality reduction in a non-high-incidence area: methodology and initial results

Contact Info

Product

Resources

About